Rational use of rapamycin (sirolimus) in modern multicomponent immunosupression after kidney transplantation
Abstract
The possibility to use rapamycin in immunosuppressive protocol, allowing early cyclosporine withdrawal in kidney transplant recipients, was investigated. Rapamycin was administered in 10 patients. There were no patient’s deaths and graft lost during follow-up period (179 ± 61 days). In one case rapamycin was stopped on day 19 because of gastrointestinal side effects. In the rest 9 cases before start of cyclosporine withdrawal graft biopsy was performed. In 5 patients morphological signs of acute rejection were found and demanded change of immunosuppressive drug combination. Rapamycin is effective immunosuppressive drug that can be used in kidney transplant recipients instead of cyclosporine in 30% of patients. Another 30% patients demand combination of rapamycin, MMF and steroids.
About the Authors
M. M. Kaabak
Российский научный центр хирургии РАМН, г. Москва
Russian Federation
Russian Federation
D. V. Samsonov
Российский научный центр хирургии РАМН, г. Москва
Russian Federation
Russian Federation
N. N. Babenko
Российский научный центр хирургии РАМН, г. Москва
Russian Federation
Russian Federation
G. F. Sheremetieva
Российский научный центр хирургии РАМН, г. Москва
Russian Federation
Russian Federation
M. M. Morozova
Российский научный центр хирургии РАМН, г. Москва
Russian Federation
Russian Federation
J. I. Kurakina
Российский научный центр хирургии РАМН, г. Москва
Russian Federation
Russian Federation
T. U. Cheprasova
Российский научный центр хирургии РАМН, г. Москва
Russian Federation
Russian Federation
References
1. Barone G.W., Gurley B.J., Abul-Ezz S.R., Gokden N. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003; 42 (1): 202-206.
2. Brazelton T.R., Morris R.E. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710-720.
3. Dumont F.J., Staruch M.J., Koprak S.L. et al. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144: 251-258.
4. Flechner S.M., Goldfarb D., Modlin C., Feng J., Krishnamurthi V., Mastroianni B., Savas K., Cook D.J., Novick A.C. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74 (8): 1070-1076.
5. El-Sabrout R., Weiss R., Butt F., Delaney V., Qadir M., Hanson P., Butt K. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients. Transplant Proc 2002; 34 (5): 1942-1943.
6. Guilbeau J.M. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002; 36 (9): 1391-1395.
7. Johnson R.W.G., Kreis H., Oberbauer R. et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786.
8. Johnson R.W., Kreis H., Oberbauer R., Brattström C., Claesson K., Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72 (5): 777-786.
9. King-Biggs M.B., Dunitz J.M., Park S.J., Kay Savik S., Hertz M.I. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75 (9): 1437-1443.
10. Lo A., Egidi M.F., Gaber L.W., Gaber A.O. Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients. Transplant Proc 2003; 35 (3 Suppl): S105-S108.
11. Mahalati K., Murphy D.M., West M.L. Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients. Transplantation 2000; 69 (7): 1531-1532.
12. Morelon E., Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35 (3); (Suppl 1): S52-S57.
13. Morelon E., Stern M., Israёl-Biet D., Correas J.M., Danel C., Mamzer-Bruneel M.F., Peraldi M.N., Kreis H. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72 (5): 787-790.
14. Morris R.E. Mechanisms of action of new immunosupressive drugs. Ther Drug Monitor 1995; 17: 564-569.
15. Morrisett J.D., Abdel-Fattah G., Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35 (3 Suppl): S143-S150.
16. Oberbauer R., Hutchison B., Eris J., Arias M., Claesson K., Mota A., Kreis H., Kleinman L., Wang F., Chen J., Revicki D.A. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial. Transplantation 2003; 75; 8: 1277-1285.
17. Oberbauer R., Kreis H., Johnson R.W.G. et al. Long-term improvement in renal function is shown in patients treated with sirolimus (Rapamune®) and cyclosporine withdrawal: 2-year results of the Rapamune® Maintenance Regimen Trial. Transplantation 2002; 74 (4): abs 254.
18. Saunders R.N., Bicknell G.R., Nicholson M.L. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75 (6): 772-780.
19. Serkova N., Litt L., James T.L., Sadee W., Leibfritz D., Benet L.Z., Christians U. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J Pharmacol Exp Ther 1999; 289 (2): 800-806.
20. Stepkowski S.M. Preclinical results of sirolimus treatment in transplant models. Transplant Proc 2003; 35 (3 Suppl): S219-S226.
Review
For citations:
Kaabak M.M., Samsonov D.V., Babenko N.N., Sheremetieva G.F., Morozova M.M., Kurakina J.I., Cheprasova T.U. Rational use of rapamycin (sirolimus) in modern multicomponent immunosupression after kidney transplantation. Nephrology and Dialysis. 2003;5(4):379-387. (In Russ.)
Views:
12
Email this article 